Open-angle glaucoma is often called a “silent” eye disease for a reason. A person may continue to read clearly, drive comfortably and carry out everyday activities while glaucoma is gradually damaging the optic nerve.
That is why glaucoma care is not based simply on how clearly you can see today.
The aim of treatment is to lower intraocular pressure (IOP) to a level considered safe for that particular eye and to slow or prevent further optic nerve damage.
Today, glaucoma treatment is no longer limited to daily eye drops. Depending on the stage of disease, target IOP and individual patient factors, treatment may include Selective Laser Trabeculoplasty (SLT) and several forms of Minimally Invasive Glaucoma Surgery (MIGS).
Clear Vision Does Not Always Mean Glaucoma Is Controlled
One of the most common misconceptions about glaucoma is:
“My vision is clear, so my glaucoma must be fine.”
Unfortunately, open-angle glaucoma can progress without obvious symptoms, particularly in its earlier stages.
Doctors therefore judge glaucoma control using several pieces of information, including:
- Intraocular pressure or IOP
- Appearance and structure of the optic nerve
- Visual field testing
- Changes seen over time
- Stage and rate of progression of glaucoma
A single “normal” pressure reading also does not necessarily mean that glaucoma is adequately controlled.
The important question is not simply, “Is the IOP normal?”
It is:
“Is this IOP low enough for this particular eye?”
This individualized pressure goal is often called the target IOP.
What Is SLT for Glaucoma?
SLT stands for Selective Laser Trabeculoplasty.
It is a laser treatment used to lower eye pressure in suitable patients with open-angle glaucoma or ocular hypertension.
SLT acts on the trabecular meshwork, an important part of the eye’s natural aqueous drainage system. The treatment helps improve aqueous outflow, which can lower IOP.
Unlike an incisional operation, SLT:
- Does not require a surgical cut
- Does not place an implant inside the eye
- Is generally performed as a clinic-based laser procedure
- Can be used relatively early in the glaucoma treatment pathway in appropriate patients
Current glaucoma guidance recognizes SLT as an early treatment option for suitable patients with open-angle glaucoma rather than reserving it only as a “last resort” after multiple medications.
Can SLT Reduce the Need for Daily Glaucoma Drops?
For many patients, this is one of the most attractive potential advantages of SLT.
In long-term follow-up from the landmark LiGHT trial, approximately 70% of eyes initially treated with SLT remained at their target IOP without glaucoma medication at six years.
This does not mean that every patient having SLT will remain drop-free for six years. Response varies between individuals, and some patients need repeat SLT, glaucoma medication or additional treatment.
However, the results show why SLT has become an important option in modern glaucoma management.
Reducing the number of daily glaucoma medicines may also have another advantage.
Fewer Eye Drops May Mean Less Ocular Surface Burden
Glaucoma treatment often continues for many years. Some patients require more than one topical medication, and chronic exposure to eye drops and preservatives can contribute to ocular surface symptoms such as:
- Burning or stinging
- Redness
- Dryness
- Foreign-body sensation
- Watering
- Difficulty tolerating multiple drops
SLT does not directly “treat dry eye.”
However, when SLT successfully reduces the number of glaucoma drops a patient requires, it can also reduce the eye's daily exposure to topical medicines and preservatives.
This can be especially relevant in patients already struggling with ocular surface discomfort.
Is SLT a Permanent Cure for Glaucoma?
No.
SLT lowers IOP; it does not cure the underlying tendency to develop glaucoma.
Its pressure-lowering effect may also reduce over time. In selected patients, repeat SLT may be considered if an initially successful response later diminishes.
Even when a patient becomes medication-free after SLT, regular glaucoma follow-up remains essential.
Glaucoma management is a long-term process.
What Happens If IOP Is Still Above Target?
If glaucoma appears insufficiently controlled, the next step is not automatically “more drops” or “surgery.”
The ophthalmologist first needs to review the entire clinical picture.
Important questions include:
- Are the prescribed drops being used correctly?
- Are doses being missed?
- Is the IOP measurement reliable?
- Is structural or visual-field progression occurring?
- What is the appropriate target IOP?
- Has SLT already been performed?
- How advanced is the glaucoma?
- Is a cataract also present?
- How much additional pressure reduction is required?
Once these factors are considered, the treatment plan may involve optimizing medications, performing or repeating SLT, considering MIGS, or choosing a stronger glaucoma operation.
What Is MIGS?
MIGS stands for Minimally Invasive Glaucoma Surgery.
Importantly, MIGS is not one single operation. It is a broad family of glaucoma procedures designed to improve aqueous drainage while generally involving less tissue disruption than traditional filtering glaucoma surgery.
MIGS is often considered in appropriately selected patients, especially when the desired pressure reduction and glaucoma severity fit the capability of the chosen procedure.
For some patients, MIGS may help:
- Lower IOP
- Reduce dependence on glaucoma medication
- Address glaucoma at the time of cataract surgery
- Provide a less invasive surgical approach than traditional filtering surgery
However, MIGS is not automatically the best surgery for every glaucoma patient.
In advanced glaucoma, or when a very low target IOP is required, traditional filtering surgery may still provide the level of pressure reduction needed.
The principle remains:
Right patient. Right target IOP. Right procedure.
MIGS Options at Madhavi Netralaya
Depending on the individual eye and clinical situation, glaucoma surgery at Madhavi Netralaya may include angle-based approaches such as:
BANG
BANG is a trabecular procedure aimed at improving aqueous outflow by treating the trabecular meshwork.
Suture GATT
GATT — Gonioscopy-Assisted Transluminal Trabeculotomy — is an angle-based procedure that treats the trabecular outflow pathway through Schlemm's canal, potentially over a broad circumferential extent.
Tanito Microhook Trabeculotomy
This ab-interno technique uses a microhook to treat the trabecular meshwork and inner wall of Schlemm's canal to improve aqueous drainage.
Dev Dual Hook Procedure
The Dev Dual Hook technique is another angle-based trabecular approach used in selected eyes as part of an individualized glaucoma surgical plan.
The appropriate technique depends on the anatomy of the eye, glaucoma stage, previous treatment, target IOP, lens status and other clinical factors.
Does Glaucoma Run in Families?
Yes. Family history is an important risk factor for primary open-angle glaucoma.
A population-based Rotterdam study found that first-degree relatives of people with glaucoma had an estimated 22% lifetime risk of glaucoma compared with 2.3% among relatives of controls, corresponding to a risk ratio of approximately 9.2 times.
Among siblings specifically, glaucoma was found in 10.4% of siblings of affected patients compared with 0.7% of siblings of controls in that study.
These are population-study figures, not a prediction of an individual person's exact risk, but they highlight an important message:
If glaucoma exists in your family, do not ignore your own eye health.
First-degree relatives include:
- Parents
- Brothers and sisters
- Children
A stronger clustering of glaucoma within a family is an additional reason to be vigilant.
A Simple Glaucoma Family-History Self-Check
Ask yourself:
- Does my mother or father have glaucoma?
- Does a brother or sister have glaucoma?
- Does my child have glaucoma?
- Are several close relatives affected?
- Do I actually know my family's eye-health history?
If you have glaucoma yourself, telling your relatives may encourage earlier eye examinations.
If glaucoma runs in your family, tell your ophthalmologist.
Top 3 Questions Patients Ask About Glaucoma
1. Can glaucoma cause blindness?
Yes. Glaucoma can cause irreversible vision loss when sufficient optic nerve damage occurs.
Treatment aims to preserve the vision that remains by slowing further damage.
2. If my IOP becomes normal, is my glaucoma cured?
No.
Reaching target IOP is an important treatment goal, but established optic nerve damage does not disappear simply because the pressure has fallen.
Continued monitoring is necessary.
3. Will glaucoma treatment continue for life?
Glaucoma usually requires long-term monitoring.
However, this does not necessarily mean using the same treatment forever.
A patient's treatment may evolve from drops to SLT, additional medications, MIGS or other glaucoma surgery according to response and disease progression.
The Takeaway
Modern glaucoma care is increasingly individualized.
For one patient, eye drops may provide excellent control. For another, SLT may provide years of pressure control with fewer or no daily glaucoma drops. In an appropriately selected surgical patient, MIGS may offer another route to lower IOP and reduce treatment burden.
What matters most is not choosing the newest treatment.
It is choosing the treatment capable of reaching the pressure target that the individual eye needs.
And because glaucoma can progress silently, regular monitoring remains important even when vision still feels completely normal.
Glaucoma Evaluation at Madhavi Netralaya, Ara
If you have glaucoma, raised eye pressure, a strong family history of glaucoma, or are exploring options such as SLT or MIGS, a comprehensive glaucoma evaluation can help determine which treatment approach may be appropriate for your eyes.
Madhavi Netralaya, Ara
Near Maharaja College Gate, South Ramna Road, Ara, Bihar 802301
24×7 Call: 1800-571-9090
Book your eye check-up · Glaucoma care at Madhavi Netralaya
Medical information on this page is intended for patient education and does not replace an individual ophthalmic examination or treatment recommendation.
